Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda and Santhera extend SNT-MC17 agreement in Europe

Takeda and Santhera extend SNT-MC17 agreement in Europe

7th August 2007

Takeda Pharmaceutical and Santhera Pharmaceuticals have announced an extension to their existing marketing agreement for SNT-MC17 (idebenone) in Switzerland and the European Union.

Under the terms of the new agreement, the companies’ partnership regarding the compound now covers a second disease – Duchenne muscular dystrophy (DMD) – an indication for which the drug is currently undergoing phase II clinical studies.

Takeda will pay Santhera an initial fee of two million euros (1.35 million pounds) and further payments up to 18 million euros on the attainment of certain landmarks, in addition to running royalty fees, while Takeda will receive exclusive marketing rights to the drug for this indication in Europe.

In July 2005, the companies had signed an agreement relating to SNT-MC17 covering the condition of Friedreich’s Ataxis (FRDA).

Yasuchika Hasegawa, president of Takeda, said: “We are pleased to have signed a second agreement with Santhera covering the European marketing rights of SNT-MC17 for the additional indication of DMD.”

He added that both DMD FRDA are serious neuromuscular conditions for which there is currently unmet medical need, with Takeda looking to introduce SNT-MC17 as a new treatment for patients with these diseases in Europe.

Earlier this month, Takeda announced the signing of an exclusive development, manufacturing and commercialisation agreement for TAK-220 and TAK-652 with Tobira Therapeutics.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.